These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24312302)

  • 1. Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity.
    Perez-Shibayama C; Gil-Cruz C; Nussbacher M; Allgäuer E; Cervantes-Barragan L; Züst R; Ludewig B
    PLoS One; 2013; 8(11):e81442. PubMed ID: 24312302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
    Cervantes-Barragan L; Züst R; Maier R; Sierro S; Janda J; Levy F; Speiser D; Romero P; Rohrlich PS; Ludewig B; Thiel V
    mBio; 2010 Sep; 1(4):. PubMed ID: 20844609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.
    Vera M; Razquin N; Prieto J; Melero I; Fortes P; González-Aseguinolaza G
    Mol Ther; 2005 Nov; 12(5):950-9. PubMed ID: 15921960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
    Lim SN; Kuhn S; Hyde E; Ronchese F
    J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
    Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
    Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells.
    Liu N; Jiang Y; Chen J; Nan H; Zhao Y; Chu X; Wang A; Wang D; Qin T; Gao S; Yi Q; Yue Y; Wang S
    Cell Mol Immunol; 2019 Jul; 16(7):644-651. PubMed ID: 30275536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells.
    Lau-Kilby AW; Kretz CC; Pechhold S; Price JD; Dorta S; Ramos H; Trinchieri G; Tarbell KV
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2408-13. PubMed ID: 21262836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector.
    Zurkova K; Babiarova K; Hainz P; Krystofova J; Kutinova L; Otahal P; Nemeckova S
    Oncol Rep; 2009 May; 21(5):1335-43. PubMed ID: 19360312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
    Moran TP; Burgents JE; Long B; Ferrer I; Jaffee EM; Tisch RM; Johnston RE; Serody JS
    Vaccine; 2007 Sep; 25(36):6604-12. PubMed ID: 17675184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
    Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
    Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
    J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.
    Thorne AH; Malo KN; Wong AJ; Nguyen TT; Cooch N; Reed C; Yan J; Broderick KE; Smith TRF; Masteller EL; Humeau L
    Front Immunol; 2020; 11():327. PubMed ID: 32161596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.